HeraMED’s (ASX:HMD) foetal ultrasound heart rate monitor has got its long awaited green light to enter the US market and it has doubled in just a few days.
The US Food and Drug Administration has approved its 510(k) application meaning it can now be sold in America. The device, HeraBEAT, is an ultra-sound device that can be utilised via users’ smart phones.
CEO David Groberman labelled FDA clearance as a “tremendous achievement” and said the device was ready to be distributed in America in the months ahead. He noted there were four million pregnancies annually in the US.
Other med tech company executives, such as Andreas Fouras from 4Dx (which is seeking ASX listing next year), have told Stockheadthe US is the hardest market to gain clearance to enter. But he also said he thought if a device could pass the US regulatory hurdles, it could make it before any regulator.
Stockhead has contacted HeraMED for further comment.
Asthma medication sensor maker Adherium (ASX:ADR) is collaborating with British social enterprise, Patient Knows Best, to support NHS commercialisation. Patients Knows best aggregates NHS data and provides patients with a full view of their health record. According to Adherium, 4 million Britons use Patient Knows Best. The partnership will mean this record will include data from Adherium’s Hailie sensors.
Prescient Therapeutics (ASX:PTX) is entering a collaboration with private stem cell therapy company Carina Biotech to develop cell therapies for cancer patients. Carina’s approach is Chimeric Antigen Receptor T cell (CAR-T cell) therapy which utilises patients’ own immune systems. Prescient CEO Steven Yatomi-Clarke said this was an exciting new frontier for the company.
share
Link copied to clipboard
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
I want the news:
Hear it first
Get the latest Stockhead news delivered free to your inbox.
Thanks! You’re subscribed, Stockhead news is coming your way soon.